RAYMOND B. WEISS, M.D.
To the editor: Santoro and colleagues (1) have reported a 59% complete response rate using the ABVD regimen (doxorubicin, bleomycin, vinblastine, and decarbazine) in patients with Hodgkin's disease resistant to MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone). For uncertain reasons other investigators (2-4) using approximately the same regimen and dose schedule have not achieved a similarly favorable rate of complete remission. One possible reason for this difference is that Santoro and associates state that 11 of their 54 evaluable patients had irradiation as "consolidation therapy" after receiving ABVD treatment. Either some of these 11 patients did not achieve a complete
Learn more about subscription options.
Register Now for a free account.
WEISS RB. Hodgkin's Disease and the ABVD Regimen. Ann Intern Med. 1982;96:784. doi: 10.7326/0003-4819-96-6-784_1
Download citation file:
Published: Ann Intern Med. 1982;96(6_part_1):784.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only